Business Description
Molecular Partners AG
ISIN : US60853G1067
Share Class Description:
MOLN: ADRCompare
Compare
Traded in other countries / regions
MOLN.SwitzerlandMOLN.USAMOLNz.UK6ML0.Germany IPO Date
2021-06-16Description
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 51.96 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 5.68 | |||||
| Beneish M-Score | 0.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -16.9 | |||||
| 3-Year EBITDA Growth Rate | 8.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.4 | |||||
| 3-Year FCF Growth Rate | -14.1 | |||||
| 3-Year Book Growth Rate | 13.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -8.38 | |||||
| Future 3-5Y Total Revenue Growth Rate | 29.03 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.85 | |||||
| 9-Day RSI | 46.9 | |||||
| 14-Day RSI | 51.82 | |||||
| 6-1 Month Momentum % | -1.62 | |||||
| 12-1 Month Momentum % | -31.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.68 | |||||
| Quick Ratio | 14.68 | |||||
| Cash Ratio | 14.18 | |||||
| Days Sales Outstanding | 92.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.1 | |||||
| Shareholder Yield % | 0.59 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -919.98 | |||||
| Net Margin % | -870.22 | |||||
| FCF Margin % | -899.05 | |||||
| ROE % | -30.19 | |||||
| ROA % | -27.17 | |||||
| ROIC % | -515.85 | |||||
| ROC (Joel Greenblatt) % | -975.67 | |||||
| ROCE % | -29.11 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.85 | |||||
| PB Ratio | 1.19 | |||||
| Price-to-Tangible-Book | 1.19 | |||||
| EV-to-EBIT | -0.54 | |||||
| EV-to-Forward-EBIT | 0.85 | |||||
| EV-to-EBITDA | -0.56 | |||||
| EV-to-Forward-EBITDA | 0.4 | |||||
| EV-to-Revenue | 4.65 | |||||
| EV-to-Forward-Revenue | 0.31 | |||||
| EV-to-FCF | -0.52 | |||||
| Price-to-Projected-FCF | 3.6 | |||||
| Price-to-Net-Current-Asset-Value | 1.23 | |||||
| Price-to-Net-Cash | 1.28 | |||||
| Earnings Yield (Greenblatt) % | -185.19 | |||||
| FCF Yield % | -29.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MOLN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Partners AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.56 | ||
| EPS (TTM) ($) | -2.01 | ||
| Beta | 1.1 | ||
| Volatility % | 113.79 | ||
| 14-Day RSI | 51.82 | ||
| 14-Day ATR ($) | 0.795677 | ||
| 20-Day SMA ($) | 6.783325 | ||
| 12-1 Month Momentum % | -31.42 | ||
| 52-Week Range ($) | 3.32 - 12.7 | ||
| Shares Outstanding (Mil) | 33.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Partners AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Partners AG Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecular Partners AG Frequently Asked Questions
What is Molecular Partners AG(MOLN)'s stock price today?
The current price of MOLN is $6.53. The 52 week high of MOLN is $12.70 and 52 week low is $3.32.
When is next earnings date of Molecular Partners AG(MOLN)?
The next earnings date of Molecular Partners AG(MOLN) is 2024-08-26.
Does Molecular Partners AG(MOLN) pay dividends? If so, how much?
Molecular Partners AG(MOLN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers